Analysts' ratings for Walgreens Boots Alliance WBA over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 0 | 5 | 3 | 0 |
Last 30D | 0 | 0 | 1 | 1 | 0 |
1M Ago | 0 | 0 | 1 | 1 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 1 | 0 | 3 | 1 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $21.11, a high estimate of $35.00, and a low estimate of $13.00. Observing a downward trend, the current average is 8.65% lower than the prior average price target of $23.11.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of Walgreens Boots Alliance among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Kevin Caliendo | UBS | Lowers | Neutral | $17.00 | $22.00 |
Steve Valiquette | Barclays | Lowers | Underweight | $19.00 | $21.00 |
Elizabeth Anderson | Evercore ISI Group | Lowers | In-Line | $17.00 | $18.00 |
Erin Wright | Morgan Stanley | Lowers | Underweight | $13.00 | $16.00 |
George Hill | Deutsche Bank | Lowers | Hold | $22.00 | $23.00 |
Charles Ryhee | TD Cowen | Lowers | Buy | $35.00 | $37.00 |
Kevin Caliendo | UBS | Lowers | Neutral | $22.00 | $25.00 |
Erin Wright | Morgan Stanley | Lowers | Underweight | $20.00 | $21.00 |
David Macdonald | Truist Securities | Maintains | Hold | $25.00 | $25.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Walgreens Boots Alliance. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Walgreens Boots Alliance compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Walgreens Boots Alliance's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Walgreens Boots Alliance's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Walgreens Boots Alliance analyst ratings.
Delving into Walgreens Boots Alliance's Background
Walgreens Boots Alliance is one of the largest retail pharmacy chains in the U.S., with over 8,500 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the U.S. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.
Walgreens Boots Alliance: Financial Performance Dissected
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Walgreens Boots Alliance showcased positive performance, achieving a revenue growth rate of 6.28% as of 29 February, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Walgreens Boots Alliance's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -15.95%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Walgreens Boots Alliance's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -35.84%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Walgreens Boots Alliance's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.49%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Walgreens Boots Alliance's debt-to-equity ratio surpasses industry norms, standing at 2.49. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.